Healthcare Sector Announces Financial Results and Financial Restatements - Research Report on Merck, Health Management

  Healthcare Sector Announces Financial Results and Financial Restatements -
  Research Report on Merck, Health Management Associates, ZELTIQ, MAKO, and
                                    Amarin

PR Newswire

NEW YORK, November 13, 2013

NEW YORK, November 13, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Merck &
Co. Inc. (NYSE: MRK), Health Management Associates Inc. (NYSE: HMA), ZELTIQ
Aesthetics, Inc. (NASDAQ: ZLTQ), MAKO Surgical Corp. (NASDAQ: MAKO), and
Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On November 9, 2013, Merck & Co. Inc. (Merck) announced data for its
investigational Timothy grass sublingual allergy immunotherapy tablet
(MK-7243) from a study involving 1,501 North American adult and pediatric
patients. According to Merck, results showed that MK-7243 significantly
improved Total Combined Score (TCS) averaged over the entire grass pollen
season (the primary endpoint), which was the sum of the rhinoconjunctivitis
daily symptom score (DSS) and the daily medication score (DMS), compared to
placebo. The Company further informed that the results of this study will be
presented in a poster titled "Efficacy and Safety of MK-7243: A Grass
Sublingual Immunotherapy Tablet Treatment in a Large Randomized Controlled
Trial in North American Children and Adults" on November 9, 2013, from 12:30 -
1:30 p.m. ET, and on November 10, 2013, from 12:30 - 1:30 p.m. ET. The Full
Research Report on Merck & Co. Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

Health Management Associates Inc. Research Report

On November 5, 2013, Health Management Associates Inc. (HMA) announced that it
will restate its financial statements for the years ended December 31, 2010,
2011 and 2012 and the quarters ended March 31 and June 30, 2013 to correct the
accounting treatment of approximately $31.0 million of Medicare and Medicaid
Health Information Technology (HCIT) payments recognized as income between
July 1, 2011 and June 30, 2013. The Company disclosed that it intends to file
the necessary amendments to its prior filings at the earliest, following which
the Company will file its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2013. According to HMA, it has concluded that, due solely to
this matter, its financial statements and related communications for FY 2010,
FY 2011 and FY 2012 as well as for the fiscal quarters ended March 31, 2013
and June 30, 2013, along with its annual 2013 guidance issued on July 30,
2013, should no longer be relied upon. The Company has filed a Current Report
on Form 8-K containing additional information concerning this matter. HMA also
reported that it is not providing annual guidance for 2013, at this time, and
the previously issued guidance provided on July 30, 2013 has been withdrawn.
The Full Research Report on Health Management Associates Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9ce8_HMA]

--

ZELTIQ Aesthetics, Inc. Research Report

On November 7, 2013, ZELTIQ Aesthetics, Inc. (ZELTIQ) announced that it has
priced an underwritten public offering of 4.5 million shares of its common
stock at a price to the public of $13.00 per share, with all the shares being
offered by selling stockholders. Underwriters have a 30-day option to purchase
up to 675,000 additional shares. The Company reported that Goldman Sachs & Co.
and J.P. Morgan Securities LLC are acting as joint book-running managers with
Canaccord Genuity Inc. and William Blair & Company, LLC acting as co-managers
for the said offering. The Full Research Report on ZELTIQ Aesthetics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b15b_ZLTQ]

--

MAKO Surgical Corp. Research Report

On November 5, 2013, MAKO Surgical Corp. (MAKO) reported its financial results
for Q3 2013. Total revenue decreased 22.0% YoY to $22.8 million. Net loss was
$21.3 million or $0.45 per diluted share, compared to $6.6 million or $0.15
per diluted share in Q3 2012. Commenting on the results, President and CEO
Maurice R. Ferré, MD, said, "MAKO's attention to the Stryker and Pipeline
transactions in the final month of the third quarter, in combination with the
announcement on September 25 of the pending MAKO - Stryker merger, had an
appreciable effect on our operating results for the quarter, especially with
respect to sales of RIO systems." The Full Research Report on MAKO Surgical
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7465_MAKO]

--

Amarin Corporation plc Research Report

On November 7, 2013, Amarin Corporation plc (Amarin) reported its financial
results for Q3 2013. Net loss was $48.9 million or $0.29 per diluted share,
compared to net loss of $26.4 million or $0.18 per diluted share in Q3 2012.
Chairman and CEO Joseph Zakrzewski said, "We continue to witness the growth of
awareness, Tier 2 managed care conversions, and prescription volume for
Vascepa, seeing an increase of 58% in normalized TRxs from Q2 to Q3 of this
year. We believe our dedicated and talented employees will be able to continue
to grow our commercial business. We also believe that the efficacy and safety
profile of Vascepa for its approved indication reflects a unique and favorably
differentiated product which is well positioned to help clinicians provide
improved care to their patients." The Full Research Report on Amarin
Corporation plc - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.